A&O Shearman U.S. and Americas’ Post

Exscientia and Recursion have entered into a definitive agreement to combine their businesses to create a leading technology-first, end-to-end drug discovery platform. “We are delighted to work with Exscientia and bring the capabilities of A&O Shearman to bear in supporting the combination with Recursion. Our work on this major life sciences transaction demonstrates the ability of A&O Shearman to bring together a multi-disciplinary transatlantic team to provide expert advice on highly complex cross border issues. It underlines the strength we bring to the global M&A marketplace.” Matthew Appleton, M&A partner Both companies are listed on Nasdaq. The transaction is expected to complete by early 2025, subject to the satisfaction or waiver of customary closing conditions including approval of both Exscientia and Recursion shareholders. Our transatlantic team, working closely alongside Exscientia general counsel Dan I., is led by M&A partners Matthew Appleton, Clare O'Brien, Nick Withers and Christopher Glenn. Get an in depth look of the broader team involved and transaction here: https://ow.ly/L9f950STL1V #AOShearman #MergersandAcquisitions